Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models
Figure 7. (A) Procedural timeline with specific timepoints. (B) Body weight and behavioral tests in SHAM, SLAB51, 6-OHDA and 6-OHDA+SLAB51 animals. ** p< 0.005, *** p< 0.0005 vs Ctr; ++ p< 0.005, +++ p< 0.0005 vs 6-OHDA.